These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 29629730

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Hereditary angioedema in Greece: the first results of the greek hereditary angioedema registry.
    Psarros F, Koutsostathis N, Farmaki E, Speletas MG, Germenis AE.
    Int Arch Allergy Immunol; 2014; 164(4):326-32. PubMed ID: 25277223
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Hide M, Fukunaga A, Maehara J, Eto K, Hao J, Vardi M, Nomoto Y.
    Arerugi; 2018; 67(2):139-147. PubMed ID: 29553114
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
    Hide M, Fukunaga A, Maehara J, Eto K, Hao J, Vardi M, Nomoto Y.
    Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405
    [Abstract] [Full Text] [Related]

  • 27. Management of acute attacks of hereditary angioedema: potential role of icatibant.
    Longhurst HJ.
    Vasc Health Risk Manag; 2010 Sep 07; 6():795-802. PubMed ID: 20859548
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain.
    Guilarte M, Sala-Cunill A, Baeza ML, Cabañas R, Hernández MD, Ibañez E, de Larramendi CH, Lleonart R, Lobera T, Marqués L, de San Pedro BS, Botha J, Andresen I, Caballero T, IOS Study Group.
    Allergy Asthma Clin Immunol; 2021 Dec 29; 17(1):137. PubMed ID: 34965883
    [Abstract] [Full Text] [Related]

  • 33. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
    Malbrán A, Riedl M, Ritchie B, Smith WB, Yang W, Banerji A, Hébert J, Gleich GJ, Hurewitz D, Jacobson KW, Bernstein JA, Khan DA, Kirkpatrick CH, Resnick D, Li H, Fernández Romero DS, Lumry W.
    Clin Exp Immunol; 2014 Aug 29; 177(2):544-53. PubMed ID: 24749847
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. How satisfactory is on-demand icatibant from the patients' perspective in real life?
    Beyaz S, Demir S, Oztop N, Colakoglu B, Buyukozturk S, Gelincik A.
    Allergy Asthma Proc; 2022 Mar 01; 43(2):148-154. PubMed ID: 35317892
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
    Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J, Craig T, Riedl M.
    Int Arch Allergy Immunol; 2015 Mar 01; 168(1):44-55. PubMed ID: 26556097
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.